Molecular analysis in a GALNS study cohort of 15 Tunisian patients: description of a novel mutation by Latifa Chkioua et al.
RESEARCH Open Access
Molecular analysis in a GALNS study cohort
of 15 Tunisian patients: description of a
novel mutation
Latifa Chkioua1,2, Souhir Khedhiri1,2, Hind Hafsi3, Oussama Grissa1, Hadhami Ben Turkia4, Abdelhedi Miled1,2,
Sandrine Laradi5, Roseline Froissart6 and Najat Alif7*
Abstract
Background: Mucopolysaccharidosis type IVA (MPS IVA) is an autosomal recessive disease caused by the deficiency
of the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). The purpose of this study was to
analyze the GALNS mutations and the haplotypes associated.
Methods: Mutation screening of the GALNS gene was performed by direct sequence analysis using DNA samples
from 15 unrelated Tunisian MPS IVA patients. We also analyzed the haplotypes associated with the novel mutation
and with the other reported GALNS mutations.
Results: We have identified an unreported missense mutation p.D288G (c.863A > G) in one patient, the most
frequently c.120 + 1G > A (IVS1 + 1G > A) mutation in eleven MPS IVA patients and three previously reported
mutations p.G66R, p.A85T and p.R386C on the other MPS IVA patients. All the studied patients were homozygous for
these identified mutations. Bioinformatics analysis predicted the novel mutation as being probably pathogenic. These
findings with the unobserved p.D288G mutation in controls subjects, suggested that it is a disease-causing mutation,
which was correlated with the severe phenotype observed in the patients. We have found that the two GALNS
unreported and reported mutations, respectively p.D288G and p.R386C, were associated with a common and
specific haplotype.
Conclusion: Our results were in agreement with previous reports from Tunisia, suggesting, on one hand the
genotype/phenotype correlations in MPS IVA patients and the other hand the haplotype analyses were useful for
determination of mutation origin in Tunisian population.
Keywords: Mucopolysaccharidosis type IVA, N-acetylgalactosamine-6-sulfatase, Mutation screening, Bioinformatics
analysis, Haplotypes
Résumé: La mucopolysccharidose de type IV A (MPS IVA) est une maladie autosomique récessive due à la déficience
de l’enzyme lysosomale N-acétylgalactosamine-6-sulfate sulfatase (GALNS). Le but de cette étude est d’analyser les
mutations du gène GALNS et les haplotypes associés.
Méthodes: Le dépistage des mutations dans le gène GALNS a été réalisé par l’analyse directe des séquences en
utilisant des échantillons d’ADN issus de 15 patients non apparentés atteints de la MPS IVA. Par ailleurs, nous avons
analysé les haplotypes associés, d’une part à la mutation nouvelle, et d’autre part, aux autres mutations déjà rapportées.
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Résultats: Nous avons identifié une nouvelle mutation faux-sens p.D288G (c.863A > G) chez un patient, la mutation la
plus fréquente c.120 + 1G > A chez onze patients et trois mutations déjà rapportées : p.G66R, p.A85T et p.R386C chez
trois patients. Tous les patients étudiés sont homozygotes pour ces mutations identifiées. Les analyses bioinformatiques
prédisent que la mutation, p.D288G, décrite pour la première fois pourrait être pathogénique. L’absence de cette
nouvelle mutation chez la population témoin suggère que la mutation p.D288G, corrélée au phénotype sévère chez le
patient étudié, est responsable de la maladie. Par ailleurs, nous avons constaté que les deux mutations du gène GALNS,
nouvelle et déjà rapportée, respectivement, p.D288G et p.R386C sont associées à un haplotype commun et spécifique.
Conclusion: Nos résultats sont en accord avec les rapports précédents de la Tunisie, ce qui suggère, d’une part les
corrélations génotype/phénotype chez les patients MPS IVA et d’autre part l’analyse des haplotypes ont été utiles pour
la détermination de l’origine de la mutation dans la population tunisienne.
Background
Mucopolysaccharidosis type IVA (MPS IVA) or Morquio
A disease (MPS IVA; OMIM 253000) is a metabolic
lysosmal and autosomal recessive disease resulting from
the deficiency of the enzyme N-acetylgalactosamine-6-
sulfate-sulfatase (GALNS: E.C.3.1.6.4), and the accumulation
of undegraded or partially degraded glycosaminoglycans
(GAGs): keratan sulfate (KS) and chondroitin-6-sulfate
(C6S) in lysosme. Phenotypes vary from the classical
form (life span of 20 to 30 years old) with corneal opa-
city, short trunk dwarfism, heart valvular disease, and
severe bone dysplasia to attenuated forms with normal
life span, mild bone and visceral complications. There
is no impairment of the central nervous system in all
Morquio A phenotypes [1, 2].
The GALNS gene, located on chromosome 16q24.3,
contains 14 exons spanning 50 kb (GDB accession ID:
129085) and is transcribed into a 1566 bp cDNA, which
encodes a 522-residue glycopeptide.
To date, more than 200 different mutations associated
with MPS IVA have been identified [Human Gene Muta-
tion Database (HGMD, 2014); http://www.hgmd.org/]
including point mutations, splice-site mutations, dele-
tions and insertions. This heterogeneity may explain the
important phenotypes variability observed in MPSIVA
patients [2–4].
Consanguineous marriages are associated with a higher
frequency of autosomal recessive disorders. Thus, firstly
an association between parental consanguinity and the
frequency of MPS IVA exists [2], secondly the impact of
consanguinity in MPS IVA was treated in several stud-
ies highlighting the major role of intermarriage in the
recurrence to have haplotype [2]. The incidence of
MPS IVA in Tunisia is also high, estimated at 0.45 in
100.000 live births [5].
In the present paper, we report the molecular analysis
of the GALNS gene in 15 MPS IVA Tunisian patients
using genomic DNA samples. We identified a novel un-
reported mutation in addition to the previously reported
ones. All the genetic lesions correlated with specific
haplotype contributing to a better understanding of the
founder effect of these mutations.
Methods
Patients
The study was carried out in 15 MPS IVA patients re-
cruited from pediatric departments of different hospitals
in Sousse, Sfax and Sidi Bouzid. All studied patients were
from a consanguineous marriage, and there were no
relationship known between the families. All proce-
dures were in accordance with the ethical standards of
the responsible committee on human experimentation
(institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000 and approved
by the Ethics Committees of the respective Tunisian
hospitals. Informed consent was obtained from all
patients and their families before being included in the
study. Additional informed consent was obtained from
all patients for whom identifying information is included
in this article.
Biochemical assay
The diagnosis of the MPSIVA disease was based on
the following approach after a clinical and paraclinical
suspicion.
Quantitative analysis of total urinary glycosaminoglycans
We first performed the study of urinary GAGs. Urinary
GAGs were quantified using a dimethylmethylene blue
(DMB) test [6].
Electrophoresis on cellulose acetate plate was per-
formed to identify the types of GAGs present in excess
(e.g., dermatan sulfate, heparan sulfate, keratan sulfate).
Discontinuous electrophoresis on cellulose acetate plates
separated the different GAGs based on their charge and
differential solubility in ethanol. The mucopolysaccha-
rides were visualized by staining with alcian blue [6].
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Table 1 Molecular and clinical findings of the fifteen MPS IVA patients
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Symptoms Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked
Growth
retardation
Short trunk + + + + + + + + +
Short neck + + + + + + + + + + + + + + +
Genu valgum Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked Marked
Corneal
opacities
+ + + + + + + + + + + + + + +








































































The GALNS enzymatic activity was measured in soni-





Genomic DNA was isolated from venous blood by the
phenol/chloroform procedure, according to standard pro-
tocols as previously described [8].. Genomic DNA of
GALNS gene was amplified and sequenced. For patients
with a family history of known or predicted pathogenic
mutations or for the index cases’ parents, targeted PCR
and sequencing were performed in the Laboratory of
Inherited Metabolic Diseases in Lyon-France.
Haplotype analysis
In order to estimate the origins of the novel missense
mutation p.D288G and the other known mutations, hap-
lotypes were determined using GALNS Sanger sequen-
cing of six amplified genomic fragments, each one
including one polymorphism [9, 10].
The mutant and normal alleles were tested for six
polymorphisms. These included the following known
polymorphisms in: (1) intron 5 (IVS5 + 134; CCAAGG
[allele A] or CCGAGG [allele a] [11], (2) exon 7 (763 nt
from A of the ATG initial codon on the cDNA;
GCACGC [allele B] or GCATGC [allele b] [12], (3) in-
tron 7 (IVS7nt90; GTAC [allele H] or GAAC [allele h]
[11], (4) exon 11 at cDNA 1232 (GTCC [allele C] or
GGCC [allele c]) [11], (5) exon 13 at cDNA 1487
(AAGCCT [allele D] or AGGCCT [allele d] [11], and (6)
exon 14 (CCAG [allele E] or CCGG [allele e] [11].
Results
The clinical features of each patient are presented in
Table 1.
Biochemical analysis
Phenotypic analysis confirmed the diagnosis of all MPS
IVA studied patients. Indeed the electrophoresis on cellu-
lose acetate plate of GAGs showed in all studied patients,
the presence of keratan sulphate (KS) an abnormal band,
compared to the control case, in addition to the band of
chondroitin sulphate (CS).
GALNS activity
Enzymatic activity was assayed in all MPS IVA patients
using fluorogenic substrates revealing low or nondetect-
able GALNS activity (Table 1).
Mutations detection
In this study, one patient was found homoallelic for the
novel A to G transition missense mutation p.D288G
(c.863A >G) (Accession#: LT576308; http://www.ebi.ac.uk/
ena/data/view/LT576308), confirmed by monodirectional
sequencing of the exon 8 of GALNS gene (Fig. 1).
The novel missense mutation p.D288G was predicted
pathogenic by Polyphen v.2. The localization of the mu-
tation was found in a conserved region among human
Fig. 1 Partial nucleotide sequence of exon VIII of GALNS gene in
MPS IVA patient homozygous for the p.D288G (a) and in control
subject (b)
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and eukaryotic sulfatases by multiple alignments in dif-
ferent species (Fig. 2).
The other 14 patients were homozygous for the four
previously reported mutations: c.120 + 1G > A, p.G66R,
p.A85T and p.R386C. The most frequent splice site mu-
tation c.120 + 1G > A was found in 73 % of all tested al-
leles. The all affected probands in this study have the
typical Morquio A phenotype.
Haplotype analysis
Haplotype analyses were performed to investigate the
eventual relationships between the studied MPS IVA
families with the splice site mutation and with the novel
missense mutation respectively.
The control subjects (n = 50) presented the unique
GALNS haplotype abcDhE. Besides, a single GALNS
haplotype was observed (aBcDEH) in the patient (homo-
allelic) with the p.D288G mutation and in patients with
the p.R386C mutation. In contrast, c.120 + 1G > A splice
site GALNS mutation was always associated with a dif-
ferent specific haplotype ABcdeH. The p.A85T and
p.G66R mutations were respectively associated with
AbCdEH and AbcDeh haplotypes (Table 1).
Discussion
In the present paper, we have screened the GALNS gene
in 15 affected MPS IVA Tunisian patients using genomic
DNA samples and performed DNA sequence analysis.
In Tunisia, the incidence for mucopolysaccharidoses
type IVA is estimated at 0.45 per 100,000 live births [13].
All affected patients studied here are offspring of con-
sanguineous marriages. First cousin inbreeding is the
most represented in Tunisia [14].
In this paper, we report for the first time the occur-
rence of the p.D288G mutation in a homoallelic MPS
IVA patient and the high incidence of the common
Tunisian MPS IVA c.120 + 1G > A mutation, for which
we confirmed the founder effect partially determined
in a previously study [15].
The p.Asp288Gly is a non conservative mutation
which leads to the substitution of an ionizable polar
amino acid (Aspartate) by an apolar amino acid
(Glycine) at position 288 of the GALNS protein.
This mutation has been identified in a patient with a
severe phenotype. It is noteworthy to precise it is lo-
cated between two other previously reported muta-
tions: p.S287L (severe phenotype [13]) and p.N289D
(severe phenotype [16]). Further analysis with more
number of MPSIVA patients will be important to
better understand the genotype–phenotype correlation.
This mutation was not present in the 100 allele’s con-
trols we tested, suggesting it is a disease-causing relation
and could be correlated with the severe phenotype ob-
served in the patient.
Haplotype analysis can provide a way to distinguish
whether a relatively common mutation results from a
founder effect or from recurrent mutations, or whether
multiple haplotypes results from a founder effect,
recurrent mutations or multiple haplotypes. The novel
missense mutation p.D288G and the previously reported
Fig. 2 a: Score of damaging mutation (Polyphen v.2); b: multiple alignment of 17 different species (http://genetics.bwh.harvard.edu/pph2/)
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missense mutation p.R386C which was identified in
Turkish patients [17] were associated with the specific
homoallelic haplotype aBcDEH in two patients. The
frequent abchDE haplotype initially identified within
normal individuals by Tomatsu (1995) [11], was identical
to the one identified in normal Tunisian controls.
In a previous study, we found that the p.W141R muta-
tion occurred in the haplotype aBhCde and the p.L390X
mutation was associated with AbhCDE [17]. These mu-
tations were not found in Tunisian MPS IVA patients
although haplotype analysis is helpful to identify the ori-
gin of different mutations.
Although the two identified mutations in this cohort
were associated with two different and specific haplotypes,
the relationship between the two mutations could not be
established because the haplotype related to p.D288G
could not be informative (found only in two patients).
More MPS IVA patients with this genetic alteration must
be analyzed.
The geographic distribution of studied patients shows
that these MPS IVA families living in different Tunisian
cities were more than 100 km away, showing the ab-
sence of relationships. However, all studied patients were
from a consanguineous marriage and had the same and
the specific haplotype. Therefore, there is a correlation
between consanguinity and GALNS polymorphism suggest-
ing that the mutant alleles were derived from a common
ancestor.
The molecular results completed the biochemical
exploration (electrophoresis profile and enzymatic ac-
tivity) and will be very helpful in case of prenatal
diagnosis which is requested due to the high inbreed-
ing rate still encountered in Tunisia. An accurate bio-
chemical analysis is available for the diagnosis of MPS
IVA. However this test was accomplished by molecu-
lar analysis for a more comprehension of the disease-
mutation relation.
Conclusion
Our report on founder mutations provides a valuable de-
cision making for the diagnosis and prevention of MPS
IVA in Tunisia. Molecular testing was a powerful tool to
investigate the role of consanguinity in all cases, con-
firming homozygosity in a consanguineous couple.
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